🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer

RecruitingNAAges 18 Years - anyMaleUniversity of Zurich
NCT07042256 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hip replacements and prostate cancer are independently and both together increasing prevalent in the aging population. In the United States, the prevalence of hip prostheses among men was 1.1 million in 20101, with approximately 500,000 hip prostheses performed annually. Bilateral total hip replacement is recommended for patients with osteoarthritis affecting both hip joints. Approximately 10-25% of total hip replacement patients undergo bilateral procedures. Stereotactic body radiotherapy (SBRT) has been widely adopted as an effective treatment for localized prostate cancer, offering high precision and reduced treatment time due to conventionally fractionated radiotherapy without increasing toxicity or comprising oncological outcomes. Therefore, the use of SBRT for treatment of localized prostate cancer has significantly increased. A cohort study using data from 302 035 patients in the

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of localized prostate cancer suitable for definitive SBRT based on a multidisciplinary tumour board recommendation and / or clinical practice guideline. * Presence of bilateral hip prostheses labeled as MR safe or MR-conditional. * ECOG performance status ≤ 2. * Signed informed consent. * Age ≥18 years - Exclusion Criteria: * Large body size that would not fit into the MRI-simulator bore * Hip prosthesis that are labeled as MR unsafe; * Contraindications to MRI including but not limited to: * Claustrophobia unmanageable by sedation * Electronic devices such as pacemakers, defibrillators, deep brain stimulators, cochlear implants that are labeled as MR unsafe, electronic devices labeled as MR safe or MR conditional are not a contraindication; * Metallic foreign body in the eye or aneurysm clips in the brain; * Clinically significant concomitant diseases that would interfere with the study (e.g. hepatic dysfunction, cardiovascular disease). * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * Enrolment of the investigator, his/her family members, employees and other dependent persons.
💊

What it tests

  • Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses
📍

Where

1 site
University Hospital Zurich, Department of Radio-Oncology
Zurich, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy